

# Hepatitis E Virus Infection in Solid Organ Transplant Recipients, France

## Technical Appendix

### Methods

#### Detection of Hepatitis E Virus (HEV) Antibodies

Anti-HEV IgM/IgG were detected by enzyme-linked immunosorbent assay (Wantai, Beijing, China).

#### Plasma HEV RNA Concentrations

HEV RNA in donor blood was detected and quantified by using a validated real-time PCR protocol with a detection limit of 100 copies/mL (i.e., 60 IU/mL) (1).

#### HEV Genotype Determination

HEV was genotyped by sequencing a 348-nt fragment within the open reading frame (ORF) 2 gene (2). The sequences were compared with reference HEV sequences (3). A confirmed case of transfusion-transmitted HEV infection requires evidence of infection in the recipient and a component of the blood from the donor testing positive for HEV RNA. It also requires that the nucleotide sequences of the 2 isolates be identical.

**Technical Appendix Table 1.** Characteristics of the 7 transplant recipients potentially infected with HEV through blood transfusion, France

Recipient	Sex	Organ transplanted	Age at ALT elevation	HEV antibody titer before transfusion,*		Interval between event and ALT elevation, mo		HEV RNA concentration at ALT elevation,	
				IgG	IgM	Transfusion	Transplantation	log copies/mL	Genotype
R1	F	Liver	34	–	–	4	3	5.9	3
R2	M	Kidney	41	–	–	1	42	3.6	3f
R3	F	Liver	42	–	–	4	4	6.6	3f
R4	F	Liver	57	+, 0.25	–	4	4	5.4	3f
R5	F	Kidney	65	–	–	4	4	4.1	3f
R6	M	Heart	44	–	–	5	7	6.8	3f
R7	F	Liver	55	+, 10.97	–	0.2	82	5.1	3c

ALT, alanine aminotransferase; HEV, hepatitis E virus.

**Technical Appendix Table 2.** Characteristics of the 7 blood donors with HEV RNA–positive, archived blood samples, France

Donor/ recipient	HEV RNA concentration, log copies/mL	Geno type	Anti-HEV IgG titer, U/mL	Anti-HEV IgM	HEV-positive blood component	Estimated transmitted volume, mL	Transfused dose of HEV RNA, log copies
D1/R1	4.7	3	+	+	Red blood cell unit	10	5.7
D2.1/R2	2.8	3c	–	–	Red blood cell unit	10	3.8
D2.2/R2	3.3	3f	+, 0.37	+	Pooled platelet concentrate	67	5.1
D2.3/R2	6.6	3f	not determined	not determined	Pooled platelet concentrate	63	8.4
D3.1/R3	4.3	3f	–	–	Amotosalen-treated plasma	209	6.6
D3.2/R3	3.0	Na	+, 2.97	+	Pooled platelet concentrate	69	4.8
D3.3/R3	2.6	Na	–	–	Pooled platelet concentrate	67	4.4

HEV, hepatitis E virus; Na, not available due to low HEV RNA concentration.

## References

1. Abravanel F, Sandres-Saune K, Lhomme S, Dubois M, Mansuy JM, Izopet J. Genotype 3 diversity and quantification of hepatitis E virus RNA. *J Clin Microbiol.* 2012;50:897–902. [PubMed](https://pubmed.ncbi.nlm.nih.gov/22511111/)  
<http://dx.doi.org/10.1128/JCM.05942-11>
2. Legrand-Abravanel F, Mansuy JM, Dubois M, Kamar N, Peron JM, Rostaing L, et al. Hepatitis E virus genotype 3 diversity, France. *Emerg Infect Dis.* 2009;15:110–4. [PubMed](https://pubmed.ncbi.nlm.nih.gov/180296/)  
<http://dx.doi.org/10.3201/eid1501.080296>
3. Smith DB, Simmonds P, Izopet J, Oliveira-Filho EF, Ulrich RG, Johne R, et al. Proposed reference sequences for hepatitis E virus subtypes. *J Gen Virol.* 2016;97:537–42. [PubMed](https://pubmed.ncbi.nlm.nih.gov/268393/)  
<http://dx.doi.org/10.1099/jgv.0.000393>